A research program to evaluate, through joint research with Osaka University and an AMED (Japan Agency for Medical Research and Development) project, the efficacy of redasemtide in acute inflammatory lung diseases, including COVID-19 pneumonia, in nonclinical studies, with the aim of initiating clinical trials.